ES2142345T3 - Procedimiento para reducir al minimo las hemorragias uterinas secundarias relacionadas con la toma de progesterona. - Google Patents

Procedimiento para reducir al minimo las hemorragias uterinas secundarias relacionadas con la toma de progesterona.

Info

Publication number
ES2142345T3
ES2142345T3 ES93913781T ES93913781T ES2142345T3 ES 2142345 T3 ES2142345 T3 ES 2142345T3 ES 93913781 T ES93913781 T ES 93913781T ES 93913781 T ES93913781 T ES 93913781T ES 2142345 T3 ES2142345 T3 ES 2142345T3
Authority
ES
Spain
Prior art keywords
progesterone
taking
procedure
uterine bleeding
minimum secondary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913781T
Other languages
English (en)
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Application granted granted Critical
Publication of ES2142345T3 publication Critical patent/ES2142345T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

SE DESCRIBRE UN METODO PARA MINIMIZAR IRREGULARIDADES EN LAS HEMORRAGIAS MENSTRUALES EN PERSONAS QUE USEN PREPARACIONES FARMACEUTICAS QUE SOLO CONTENGAN PROGESTINA, TALES COMO ANTICONCEPTIVOS
ES93913781T 1992-05-06 1993-05-03 Procedimiento para reducir al minimo las hemorragias uterinas secundarias relacionadas con la toma de progesterona. Expired - Lifetime ES2142345T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/003574 WO1993021926A1 (en) 1992-05-06 1992-05-06 Minimizing progestin associated breakthrough bleeding

Publications (1)

Publication Number Publication Date
ES2142345T3 true ES2142345T3 (es) 2000-04-16

Family

ID=22231028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913781T Expired - Lifetime ES2142345T3 (es) 1992-05-06 1993-05-03 Procedimiento para reducir al minimo las hemorragias uterinas secundarias relacionadas con la toma de progesterona.

Country Status (17)

Country Link
EP (1) EP0646008B1 (es)
JP (1) JP3937240B2 (es)
KR (1) KR950700745A (es)
CN (1) CN1073422C (es)
AT (1) ATE187644T1 (es)
AU (2) AU1918092A (es)
CA (1) CA2131911C (es)
DE (1) DE69327319T2 (es)
DK (1) DK0646008T3 (es)
ES (1) ES2142345T3 (es)
FI (1) FI945207A0 (es)
GR (1) GR3032797T3 (es)
NO (1) NO308581B1 (es)
NZ (1) NZ253405A (es)
PT (1) PT646008E (es)
WO (2) WO1993021926A1 (es)
ZA (1) ZA933153B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
ES2218556T3 (es) * 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
WO1996023503A1 (de) * 1995-02-02 1996-08-08 Schering Aktiengesellschaft Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
NZ332894A (en) * 1996-06-25 1999-05-28 Akzo Nobel Nv A regimen containing progestogen and/or estrogen with two or more anti-progestogen dosage units
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
TR200001334T2 (tr) * 1997-11-14 2000-09-21 Akzo Nobel N.V. Progestojen-anti-progestojen rejimleri.
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
SK15502001A3 (sk) * 1999-04-29 2002-03-05 Akzo Nobel N. V. Použitie Org 33245
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935617B (en) * 1992-08-14 1994-03-07 Akzo Nv Antiprogestogen containing contraceptives.

Also Published As

Publication number Publication date
CN1073422C (zh) 2001-10-24
FI945207L (fi) 1994-11-04
DK0646008T3 (da) 2000-05-15
CA2131911C (en) 2005-12-27
ZA933153B (en) 1993-12-06
GR3032797T3 (en) 2000-06-30
NO944210D0 (no) 1994-11-04
AU667729B2 (en) 1996-04-04
ATE187644T1 (de) 2000-01-15
JPH08509456A (ja) 1996-10-08
JP3937240B2 (ja) 2007-06-27
EP0646008B1 (en) 1999-12-15
FI945207A7 (fi) 1994-11-04
AU1918092A (en) 1993-11-29
NZ253405A (en) 1997-06-24
CN1079651A (zh) 1993-12-22
EP0646008A4 (en) 1995-10-11
NO308581B1 (no) 2000-10-02
PT646008E (pt) 2000-04-28
DE69327319T2 (de) 2000-07-13
CA2131911A1 (en) 1993-11-11
DE69327319D1 (de) 2000-01-20
NO944210L (no) 1994-11-04
FI945207A0 (fi) 1994-11-04
EP0646008A1 (en) 1995-04-05
WO1993021926A1 (en) 1993-11-11
KR950700745A (ko) 1995-02-20
AU4368593A (en) 1993-11-29
WO1993021927A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
ES2142345T3 (es) Procedimiento para reducir al minimo las hemorragias uterinas secundarias relacionadas con la toma de progesterona.
TR199802705T2 (xx) Progestojen-anti-progestojen k�r�
NO976067D0 (no) Farmasöytisk kombinasjonspreparat, sett og fremgangsmåte for hormonell prevensjon
DE69118494D1 (de) Kontrazeptionsverfahren und Schema
ATE241361T1 (de) Mittel zur hormonalen kontrazeption
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
FI903106A0 (fi) Preventivsystem och -foerfarande.
DK282784A (da) 1-alkyl-androsta-1,4-dien-3,17-dioner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende dem
GB2004741A (en) Cosmetic and pharmaceutical compositions for the skin
FI971742A7 (fi) Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskauden ehkäisyyn naisilla
ES2180690T3 (es) Preparacion de composiciones que comprenden st1435 para aplicacion topica.
ATE91410T1 (de) Osmotische dosierungsform.
JPS5464629A (en) Contraceptive for vagina
BR0318192A (pt) regimes contraceptivos transdérmicos prolongados
ES502552A0 (es) Procedimiento para la preparacion de un nonapeptido
MX9300676A (es) Procedimiento para la preparacion de dienos esteroidales subtituidos.
MY100443A (en) Topical preparation for treating herpes simplex virus infection
TH14144A (th) การลดการสูญเสียโลหิตแบบไหลออกที่เกิดจากการใช้โปรเกสทิน
UA19520A (uk) Спосіб дородової підготовки шийки матки
ZA785125B (en) Novel delta4,9-pregnane derivatives,their use as progestational and/or ovulation-inhibiting agents and process for their preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 646008

Country of ref document: ES